Request History

• Restore to current request
• applications/index/page:2/sort:study_title/direction:asc/status:approved
• applications/index/sort:approval_date/direction:asc/trial_therapeutic_use:1/status:approved
• applications/index/sort:trial_status_date/direction:asc/trial_therapeutic_use:1/status:stopped
• applications/index/page:2/sort:approval_date/direction:desc/status:approved

Session

• Config(array)
  • userAgent9c3d2c89526db53b7b69e8c9faa06145
  • time1790949592
  • countdown10

Request

Cake Params

• plugin(null)
• controllerapplications
• actionindex
• named(array)
  • page2
  • sortprotocol_no
  • directionasc
  • statusapproved
• pass(empty)
• isAjax(false)
• paging(array)
  • Application(array)
    • page2
    • current10
    • count26
    • prevPage(true)
    • nextPage(true)
    • pageCount3
    • order(array)
      • Application.protocol_noasc
    • limit10
    • options(array)
      • page2
      • order(array)
        • Application.protocol_noasc
      • sortprotocol_no
      • directionasc
    • paramTypenamed

Post data

• Application(array)
  • statusapproved

Query string

No querystring data.

Cookie

To view Cookies, add CookieComponent to Controller

Current Route

• keys(array)
  • 0controller
  • 1action
• options(empty)
• defaults(array)
  • plugin(null)
• template/:controller/:action/*

Sql Logs

Logs

View Variables

• trial_statuses(array)
  • 1Recruiting
  • 2Not yet recruiting
  • 3Suspended
  • 4Stopped
  • 5Completed
  • 6In follow-up
  • 7Analysing
  • 8Writing-up
  • 9Application withdrawn
  • 10Paused or preparation for extension of study
  • 11Revoked
  • 12Ongoing Closeout Phase
• action_date_fieldapproval_date
• statusapproved
• applications(array)
  • 0(array)
    • Application(array)
      • id191
      • user_id26
      • application_id99
      • is_child1
      • trial_status_id(null)
      • trial_status_date(null)
      • total_sites1
      • abstract_of_study<p>\n This prospective multi-center study aims to evaluate the impact of telemedicine on postoperative recovery in patients who have undergone cardiac surgery. A total of 500 patients from five major hospitals will be enrolled and monitored for six months post-surgery. Participants will be divided into two groups: one receiving traditional in-person follow-up care, and the other receiving regular telemedicine consultations. Primary outcomes include readmission rates, complication rates, and patient satisfaction. Secondary outcomes focus on recovery time and healthcare costs. Initial findings indicate that telemedicine may enhance patient outcomes by providing timely medical advice and reducing the need for hospital visits. This study will contribute to understanding the role of telemedicine in improving postoperative care for cardiac surgery patients.</p>\n
      • study_title<p>\n Evaluating the Impact of Telemedicine on Postoperative Recovery in Cardiac Surgery Patients: A Multi-Center Prospective Study</p>\n
      • laymans_summary<p>\n This research looks at how using telemedicine (video calls with doctors) affects recovery after heart surgery. By studying patients from multiple hospitals, the researchers aim to see if virtual follow-ups can help patients heal better and faster compared to traditional in-person visits.</p>\n
      • short_titlestudy 4
      • protocol_noECCT/24/06/04 - A
      • reference_no
      • version_no1.0
      • date_of_protocol20-06-2024
      • study_drugCanagliflozin
      • disease_conditionType 2 Diabetes Mellitus
      • product_type_biologicals1
      • product_type_proteins1
      • product_type_immunologicals0
      • product_type_vaccines1
      • product_type_hormones0
      • product_type_toxoid0
      • product_type_chemical1
      • product_type_medical_device0
      • product_type_chemical_nameCanagliflozin
      • product_type_medical_device_name
      • comparatorNo
      • comparator_name
      • comparator_registered
      • comparator_countries
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjayoma@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantJames McCurrly
      • declaration_date120-06-2024
      • declaration_principal_investigatorPI Inv
      • declaration_date220-06-2024
      • protocol_not_ai_generated0
      • placebo_presentNo
      • study_objectives<ul>\n <li>\n <p>\n <strong>Primary Objective:</strong></p>\n <ul>\n <li>\n To investigate the effect of canagliflozin on glycemic control, measured by changes in HbA1c levels, in patients with type 2 diabetes mellitus over a 24-week treatment period.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Secondary Objective:</strong></p>\n <ul>\n <li>\n To assess changes in body weight, blood pressure, and lipid profile in patients treated with canagliflozin.</li>\n <li>\n To evaluate the safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus.</li>\n <li>\n To explore patient-reported outcomes related to quality of life and treatment satisfaction with canagliflozin therapy.</li>\n </ul>\n </li>\n</ul>\n
      • principal_inclusion_criteria<ul>\n <li>\n <p>\n <strong>Type 2 Diabetes Mellitus diagnosis:</strong></p>\n <ul>\n <li>\n Patients must have a documented diagnosis of type 2 diabetes mellitus.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Inadequate glycemic control:</strong></p>\n <ul>\n <li>\n Patients must have inadequate glycemic control defined as HbA1c levels between 7.5% and 10.5% despite treatment with stable doses of metformin alone or in combination with other oral antidiabetic agents</li>\n </ul>\n </li>\n</ul>\n
      • principal_exclusion_criteria<ul>\n <li>\n <p>\n <strong>Renal impairment:</strong></p>\n <ul>\n <li>\n Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) or end-stage renal disease requiring dialysis are excluded.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Cardiovascular events:</strong></p>\n <ul>\n <li>\n Patients with a history of recent cardiovascular events such as myocardial infarction, stroke, or unstable angina within the past 3 months are excluded.</li>\n </ul>\n </li>\n</ul>\n
      • primary_end_points<ul>\n <li>\n <p>\n <strong>Primary Endpoint 1: Change in HbA1c Levels</strong></p>\n <ul>\n <li>\n The primary endpoint is the change in HbA1c levels from baseline to week 24 in patients treated with canagliflozin compared to placebo or standard treatment. HbA1c reflects average blood glucose levels over the past 2-3 months and is a key measure of glycemic control in diabetes.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Primary Endpoint 2: Incidence of Adverse Cardiovascular Events</strong></p>\n <ul>\n <li>\n Another primary endpoint is the incidence of adverse cardiovascular events (e.g., myocardial infarction, stroke, cardiovascular death) during the treatment period with canagliflozin compared to placebo or standard treatment. This endpoint assesses the cardiovascular safety profile of canagliflozin in patients with type 2 diabetes mellitus.</li>\n </ul>\n </li>\n</ul>\n
      • scope_diagnosis1
      • scope_prophylaxis0
      • scope_therapy1
      • scope_safety0
      • scope_efficacy1
      • scope_pharmacokinetic0
      • scope_pharmacodynamic0
      • scope_bioequivalence0
      • scope_dose_response0
      • scope_pharmacogenetic0
      • scope_pharmacogenomic0
      • scope_pharmacoecomomic0
      • scope_others0
      • scope_others_specify
      • trial_human_pharmacology0
      • trial_administration_humans0
      • trial_bioequivalence_study0
      • trial_other0
      • trial_other_specify
      • trial_therapeutic_exploratory0
      • trial_therapeutic_confirmatory1
      • trial_therapeutic_use0
      • design_controlledNo
      • site_capacity(null)
      • staff_numbers<p>\n <strong>Capacity of Site:</strong></p>\n<ul>\n <li>\n Leading academic medical center with extensive research capabilities.</li>\n</ul>\n<p>\n <strong>Number of Staff and Facilities:</strong></p>\n<ul>\n <li>\n <p>\n <strong>Study Coordinators:</strong></p>\n <ul>\n <li>\n Laura Marie Smith, MD, FACP (Coordinating Investigator)</li>\n <li>\n John William Davies, PharmD (Pharmacist)</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Other Staff:</strong></p>\n <ul>\n <li>\n Specialists in endocrinology, diabetes, and metabolism.</li>\n <li>\n Research nurses, clinical trial coordinators.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Site Facilities:</strong></p>\n <ul>\n <li>\n Advanced laboratories for research.</li>\n <li>\n Comprehensive patient care facilities.</li>\n <li>\n High-tech diagnostic and treatment equipment.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Emergency Facilities:</strong></p>\n <ul>\n <li>\n Level I trauma center.</li>\n <li>\n Rapid response teams and critical care capabilities.</li>\n </ul>\n </li>\n</ul>\n
      • other_details_explanation<ol>\n <li>\n <ul>\n <li>\n Kenya has a significant prevalence of type 2 diabetes mellitus, providing a suitable patient population for studying the efficacy and safety of canagliflozin. This ensures adequate enrollment of eligible participants.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Ethnic Diversity and Genetic Variability:</strong></p>\n <ul>\n <li>\n The ethnic diversity in Kenya offers an opportunity to study the response to canagliflozin across different genetic backgrounds. Understanding genetic variability can provide insights into personalized treatment approaches.</li>\n </ul>\n </li>\n</ol>\n<p>\n  </p>\n
      • other_details_regulatory_notapproved<p>\n <strong>Name of Regulatory Authorities:</strong></p>\n<ul>\n <li>\n MHRA (Medicines and Healthcare products Regulatory Agency), UK</li>\n <li>\n TGA (Therapeutic Goods Administration), Australia</li>\n</ul>\n<p>\n <strong>Date(s) of Application:</strong></p>\n<ul>\n <li>\n MHRA: March 10, 2024</li>\n <li>\n TGA: April 5, 2024</li>\n</ul>\n
      • other_details_regulatory_approved<ul>\n <li>\n <p>\n <strong>MHRA (Medicines and Healthcare products Regulatory Agency), UK</strong></p>\n <ul>\n <li>\n <strong>Date of Approval:</strong> April 20, 2024</li>\n <li>\n <strong>Number of Sites per Country:</strong>\n <ul>\n <li>\n UK: 12 sites</li>\n </ul>\n </li>\n </ul>\n </li>\n <li>\n <p>\n <strong>TGA (Therapeutic Goods Administration), Australia</strong></p>\n <ul>\n <li>\n <strong>Date of Approval:</strong> May 5, 2024</li>\n <li>\n <strong>Number of Sites per Country:</strong>\n <ul>\n <li>\n Australia: 8 sites</li>\n </ul>\n </li>\n </ul>\n </li>\n</ul>\n
      • other_details_regulatory_rejected<p>\n N/A</p>\n
      • other_details_regulatory_halted<p>\n N/A</p>\n
      • estimated_duration24 months
      • design_controlled_randomised
      • design_controlled_open
      • design_controlled_single_blind
      • design_controlled_double_blind
      • design_controlled_parallel_group
      • design_controlled_cross_over
      • design_controlled_other
      • design_controlled_specify
      • design_controlled_comparator
      • design_controlled_other_medicinal
      • design_controlled_placebo
      • design_controlled_medicinal_other
      • design_controlled_medicinal_specify
      • single_site_member_stateYes
      • location_of_areatest site2
      • single_site_physical_addressTEST
      • single_site_contact_personJoel Justin
      • single_site_telephone+254709283746
      • multiple_sites_member_stateNo
      • multiple_countriesNo
      • multiple_member_states
      • number_of_sites
      • multi_country_list
      • data_monitoring_committeeYes
      • total_enrolment_per_site200000
      • total_participants_worldwide20000000
      • population_less_than_18_yearsYes
      • population_uteroNo
      • population_preterm_newbornNo
      • population_newbornNo
      • population_infant_and_toddlerYes
      • population_childrenYes
      • population_adolescentYes
      • population_above_18Yes
      • population_adultYes
      • population_elderlyYes
      • gender_female1
      • gender_male0
      • subjects_healthyNo
      • subjects_patientsYes
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingYes
      • subjects_women_using_contraceptionYes
      • subjects_pregnant_womenYes
      • subjects_nursing_womenYes
      • subjects_emergency_situationYes
      • subjects_incapable_consentNo
      • subjects_specify
      • subjects_othersNo
      • subjects_others_specify
      • investigator1_given_nameMichael
      • investigator1_middle_name
      • investigator1_family_nameThompson
      • investigator1_qualificationMD, MPH
      • investigator1_professional_addressDepartment of Medicine University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Houston, TX 77030 United States
      • investigator1_telephone +1 713-792-2121
      • investigator1_emailmathompson@mdanderson.org
      • organisations_transferred_No
      • number_participants2000000
      • notification<p>\n N/A</p>\n
      • approval_date11-04-2025
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted18-02-2025
      • unsubmitted1
      • initial_date_submitted20-06-2024
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reason
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice305957
      • modified2025-04-11 08:01:54
      • created2025-02-18 09:40:19
      • ai_content(null)
    • InvestigatorContact(array)
      • 0(array)
        • id110
        • application_id191
        • given_nameJavan
        • middle_name
        • family_nameAyoma
        • qualificationMasters
        • professional_addressMsc Drive
        • telephone+254702674563
        • emailjayoma@intellisoftkenya.com
        • investigator_roleprincipal
        • created2024-06-20 10:44:12
        • modified2025-02-18 09:59:26
    • SiteDetail(array)
      • 0(array)
        • id1748
        • application_id191
        • county_id(null)
        • site_name
        • physical_address
        • contact_details
        • contact_person
        • site_capacity(null)
        • misc(null)
        • created2024-06-20 10:55:03
        • modified2025-02-18 09:59:26
        • County(empty)
    • Sponsor(array)
      • 0(array)
        • id46
        • application_id191
        • sponsorBioPharma Innovations Ltd.
        • sponsor_typeIndustry
        • contact_person
        • addressBioPharma Innovations Ltd. 123 Main Street San Francisco, CA 94105 United States
        • telephone_number+1 415-555-6789
        • fax_number
        • cell_number+1 415-555-6778
        • email_addressinfo@biopharmainnovations.com
        • created2024-06-20 10:55:03
        • modified2025-02-18 09:59:26
    • PublicAction(array)
      • labelApproved
      • date11-04-2025
  • 1(array)
    • Application(array)
      • id98
      • user_id26
      • application_id(null)
      • is_child0
      • trial_status_id(null)
      • trial_status_date(null)
      • total_sites2
      • abstract_of_study<p>\n  This randomized controlled trial investigates the efficacy and safety of a novel immunotherapy in patients with advanced melanoma. A total of 300 participants will be randomly assigned to receive either the new immunotherapy or a standard treatment. The primary outcome measures include overall survival rate, progression-free survival, and incidence of adverse events over a 24-month period. Secondary outcomes will assess quality of life and biomarker responses. Preliminary data suggests that the new therapy may improve survival rates with manageable side effects. This study aims to provide robust evidence on the potential benefits and risks of this innovative treatment, potentially offering a new standard of care for advanced melanoma patients.</p>\n<p>\n  </p>\n
      • study_title<p>\n Efficacy and Safety of Novel Immunotherapy in Treating Advanced Melanoma: A Randomized Controlled Tria</p>\n
      • laymans_summary<p>\n This study tests a new treatment for advanced skin cancer (melanoma). Researchers are checking if this new therapy is both effective and safe. They are comparing it to other treatments by giving it to some patients and not others, then seeing how well it works and if there are any side effects.</p>\n
      • short_titleStudy 3
      • protocol_noECCT/24/06/05
      • reference_no(null)
      • version_no1.2
      • date_of_protocol20-06-2024
      • study_drugNivolumab
      • disease_condition Non-Small Cell Lung Cancer (NSCLC)
      • product_type_biologicals1
      • product_type_proteins1
      • product_type_immunologicals0
      • product_type_vaccines0
      • product_type_hormones0
      • product_type_toxoid0
      • product_type_chemical1
      • product_type_medical_device0
      • product_type_chemical_name Nivolumab
      • product_type_medical_device_name
      • comparatorNo
      • comparator_name
      • comparator_registered
      • comparator_countries
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjayoma@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantJospeh McCathy
      • declaration_date120-06-2024
      • declaration_principal_investigatorPI Inv
      • declaration_date220-06-2024
      • protocol_not_ai_generated0
      • placebo_presentYes
      • study_objectives<ol>\n <li>\n <p>\n <strong>Primary Objective:</strong></p>\n <ul>\n <li>\n To compare the overall survival (OS) of patients with advanced melanoma treated with nivolumab versus standard-of-care chemotherapy.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Secondary Objective:</strong></p>\n <ul>\n <li>\n To assess the progression-free survival (PFS) in patients receiving nivolumab compared to those receiving standard chemotherapy.</li>\n <li>\n To evaluate the safety profile and incidence of adverse events associated with nivolumab treatment.</li>\n <li>\n To explore biomarkers that may predict response to nivolumab therapy in advanced melanoma patients.</li>\n </ul>\n </li>\n</ol>\n<h3>\n  </h3>\n
      • principal_inclusion_criteria<ul>\n <li>\n <p>\n <strong>Histologically confirmed diagnosis of advanced melanoma:</strong></p>\n <ul>\n <li>\n Patients must have histologically confirmed unresectable stage III or stage IV melanoma.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Prior treatment history:</strong></p>\n <ul>\n <li>\n Patients must have received prior treatment with a BRAF inhibitor (if BRAF V600 mutation positive) or have progressed on or after anti-PD-1/L1 therapy.</li>\n </ul>\n </li>\n</ul>\n
      • principal_exclusion_criteria<ol>\n <li>\n <p>\n <strong>Autoimmune disease:</strong></p>\n <ul>\n <li>\n Patients with a history of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) requiring systemic treatment within the past 2 years are excluded.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Active brain metastases:</strong></p>\n <ul>\n <li>\n Patients with untreated or symptomatic brain metastases are excluded unless they have completed local therapy and are neurologically stable without corticosteroid treatment for at least 4 weeks.</li>\n </ul>\n </li>\n</ol>\n
      • primary_end_points<ul>\n <li>\n <p>\n <strong>Primary Endpoint 1: Overall Survival (OS)</strong></p>\n <ul>\n <li>\n The primary endpoint is the comparison of overall survival between patients treated with nivolumab and those receiving standard chemotherapy. OS is defined as the time from randomization until death from any cause.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Primary Endpoint 2: Progression-Free Survival (PFS)</strong></p>\n <ul>\n <li>\n Another primary endpoint is the comparison of progression-free survival between the nivolumab and standard chemotherapy groups. PFS is defined as the time from randomization to disease progression or death from any cause, whichever occurs first.</li>\n </ul>\n </li>\n</ul>\n
      • scope_diagnosis0
      • scope_prophylaxis1
      • scope_therapy0
      • scope_safety0
      • scope_efficacy0
      • scope_pharmacokinetic0
      • scope_pharmacodynamic0
      • scope_bioequivalence1
      • scope_dose_response1
      • scope_pharmacogenetic0
      • scope_pharmacogenomic0
      • scope_pharmacoecomomic0
      • scope_others0
      • scope_others_specify
      • trial_human_pharmacology0
      • trial_administration_humans0
      • trial_bioequivalence_study0
      • trial_other0
      • trial_other_specify
      • trial_therapeutic_exploratory0
      • trial_therapeutic_confirmatory0
      • trial_therapeutic_use1
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n <strong>Capacity of Site:</strong></p>\n<ul>\n <li>\n Specializes in oncology research and treatment.</li>\n <li>\n Large capacity for clinical trials with dedicated research units.</li>\n</ul>\n<p>\n <strong>Number of Staff and Facilities:</strong></p>\n<ul>\n <li>\n <p>\n <strong>Study Coordinators:</strong></p>\n <ul>\n <li>\n Sarah Elizabeth Johnson, MD, PhD (Coordinating Investigator)</li>\n <li>\n Emily Jane Carter, PharmD (Pharmacist)</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Other Staff:</strong></p>\n <ul>\n <li>\n Oncologists, nurses, research assistants with experience in oncology.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Site Facilities:</strong></p>\n <ul>\n <li>\n State-of-the-art research labs.</li>\n <li>\n Dedicated infusion centers.</li>\n <li>\n Imaging facilities (MRI, CT scans).</li>\n <li>\n Patient monitoring and emergency response systems.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Emergency Facilities:</strong></p>\n <ul>\n <li>\n Close proximity to emergency departments within the hospital.</li>\n <li>\n Dedicated emergency response teams for clinical trials.</li>\n </ul>\n </li>\n</ul>\n
      • other_details_explanation<p>\n <strong>Reasons for Conducting the Trial in Kenya:</strong></p>\n<ol>\n <li>\n <p>\n <strong>Access to Diverse Patient Population:</strong></p>\n <ul>\n <li>\n Kenya offers access to a diverse population of patients with advanced melanoma who may have different genetic backgrounds and disease characteristics compared to the host country of the sponsor. This diversity enhances the generalizability of study findings.</li>\n </ul>\n </li>\n <li>\n <p>\n <strong>Clinical Trial Infrastructure:</strong></p>\n <ul>\n <li>\n Kenya has established clinical trial infrastructure, including research centers and experienced healthcare professionals, capable of conducting oncology trials. This infrastructure supports efficient patient recruitment and trial execution.</li>\n </ul>\n </li>\n</ol>\n<h3>\n  </h3>\n
      • other_details_regulatory_notapproved<p>\n <strong>Name of Regulatory Authorities:</strong></p>\n<ul>\n <li>\n FDA (Food and Drug Administration), USA</li>\n <li>\n EMA (European Medicines Agency), EU</li>\n</ul>\n<p>\n <strong>Date(s) of Application:</strong></p>\n<ul>\n <li>\n FDA: January 15, 2024</li>\n <li>\n EMA: February 1, 2024</li>\n</ul>\n<h3>\n  </h3>\n
      • other_details_regulatory_approved<ul>\n <li>\n <p>\n <strong>FDA (Food and Drug Administration), USA</strong></p>\n <ul>\n <li>\n <strong>Date of Approval:</strong> May 15, 2024</li>\n <li>\n <strong>Number of Sites per Country:</strong>\n <ul>\n <li>\n USA: 25 sites</li>\n </ul>\n </li>\n </ul>\n </li>\n <li>\n <p>\n <strong>EMA (European Medicines Agency), EU</strong></p>\n <ul>\n <li>\n <strong>Date of Approval:</strong> June 1, 2024</li>\n <li>\n <strong>Number of Sites per Country:</strong>\n <ul>\n <li>\n Germany: 15 sites</li>\n <li>\n France: 10 sites</li>\n <li>\n Spain: 8 sites</li>\n </ul>\n </li>\n </ul>\n </li>\n</ul>\n
      • other_details_regulatory_rejected<p>\n N/A</p>\n
      • other_details_regulatory_halted<p>\n N/A</p>\n
      • estimated_duration36months
      • design_controlled_randomisedYes
      • design_controlled_openYes
      • design_controlled_single_blindNo
      • design_controlled_double_blindNo
      • design_controlled_parallel_groupYes
      • design_controlled_cross_overYes
      • design_controlled_otherNo
      • design_controlled_specify
      • design_controlled_comparatorcomparator1
      • design_controlled_other_medicinalNo
      • design_controlled_placeboYes
      • design_controlled_medicinal_otherNo
      • design_controlled_medicinal_specify
      • single_site_member_stateYes
      • location_of_areaSite1
      • single_site_physical_addressadmin site
      • single_site_contact_personTest
      • single_site_telephone+254790192
      • multiple_sites_member_stateNo
      • multiple_countriesNo
      • multiple_member_states
      • number_of_sites
      • multi_country_list
      • data_monitoring_committeeYes
      • total_enrolment_per_site200000
      • total_participants_worldwide200000000
      • population_less_than_18_yearsNo
      • population_uteroNo
      • population_preterm_newbornNo
      • population_newbornNo
      • population_infant_and_toddlerNo
      • population_childrenNo
      • population_adolescentNo
      • population_above_18Yes
      • population_adultYes
      • population_elderlyYes
      • gender_female0
      • gender_male1
      • subjects_healthyNo
      • subjects_patientsNo
      • subjects_vulnerable_populationsNo
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionNo
      • subjects_pregnant_womenNo
      • subjects_nursing_womenNo
      • subjects_emergency_situationNo
      • subjects_incapable_consentNo
      • subjects_specify
      • subjects_othersNo
      • subjects_others_specify
      • investigator1_given_nameSarah
      • investigator1_middle_name
      • investigator1_family_nameJohnson
      • investigator1_qualificationMD, PhD
      • investigator1_professional_addressDepartment of Oncology Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10065 United States
      • investigator1_telephone+1 212-639-2000
      • investigator1_emailsjohnson@mskcc.org
      • organisations_transferred_Yes
      • number_participants200000
      • notification<p>\n NA</p>\n
      • approval_date20-06-2024
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted20-06-2024
      • unsubmitted1
      • initial_date_submitted20-06-2024
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reason
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice305955
      • modified2024-07-16 10:06:14
      • created2024-06-20 10:32:00
      • ai_content(null)
    • InvestigatorContact(array)
      • 0(array)
        • id53
        • application_id98
        • given_nameJavan
        • middle_name
        • family_nameAyoma
        • qualificationMasters
        • professional_addressMsc
        • telephone+254702674563
        • emailjayoma@intellisoftkenya.com
        • investigator_roleprincipal
        • created2024-06-20 10:32:00
        • modified2024-06-25 08:51:45
    • SiteDetail(array)
      • 0(array)
        • id1701
        • application_id98
        • county_id(null)
        • site_name
        • physical_address
        • contact_details
        • contact_person
        • site_capacity(null)
        • misc(null)
        • created2024-06-20 10:55:30
        • modified2024-06-25 08:51:45
        • County(empty)
    • Sponsor(array)
      • 0(array)
        • id23
        • application_id98
        • sponsorBioPharma Innovations Ltd.
        • sponsor_typeIndustry
        • contact_person
        • addressBioPharma Innovations Ltd. 123 Main Street San Francisco, CA 94105 United States
        • telephone_number+1 415-555-6789
        • fax_number
        • cell_number+1 415-555-6778
        • email_addressinfo@biopharmainnovations.com
        • created2024-06-20 10:55:30
        • modified2024-06-25 08:51:45
    • PublicAction(array)
      • labelApproved
      • date20-06-2024
  • 2(array)
    • Application(array)
      • id120
      • user_id82
      • application_id(null)
      • is_child0
      • trial_status_id(null)
      • trial_status_date(null)
      • total_sites1
      • abstract_of_study<p>\n studyabstract</p>\n
      • study_title<p>\n abstract 123</p>\n
      • laymans_summary<p>\n layman</p>\n
      • short_titleuser
      • protocol_noECCT/24/10/02
      • reference_no(null)
      • version_no2
      • date_of_protocol09-10-2024
      • study_drugstudydrug
      • disease_conditionmalaria
      • product_type_biologicals1
      • product_type_proteins1
      • product_type_immunologicals0
      • product_type_vaccines0
      • product_type_hormones0
      • product_type_toxoid0
      • product_type_chemical0
      • product_type_medical_device0
      • product_type_chemical_name
      • product_type_medical_device_name
      • comparatorNo
      • comparator_name
      • comparator_registered
      • comparator_countries
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addresslchepkwony@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantDeleniti et autem ea omnis
      • declaration_date104-05-2023
      • declaration_principal_investigatorQuaerat aspernatur consequatur non voluptas inventore ad officiis do consequatur voluptates enim asperiores minim illum
      • declaration_date218-01-2014
      • protocol_not_ai_generated0
      • placebo_presentYes
      • study_objectives<p>\n objective</p>\n
      • principal_inclusion_criteria<p>\n inclusion</p>\n
      • principal_exclusion_criteria<p>\n exclusion</p>\n
      • primary_end_points<p>\n end point</p>\n
      • scope_diagnosis1
      • scope_prophylaxis1
      • scope_therapy0
      • scope_safety1
      • scope_efficacy0
      • scope_pharmacokinetic0
      • scope_pharmacodynamic0
      • scope_bioequivalence1
      • scope_dose_response0
      • scope_pharmacogenetic0
      • scope_pharmacogenomic0
      • scope_pharmacoecomomic1
      • scope_others1
      • scope_others_specifySit ut lorem ut vel
      • trial_human_pharmacology1
      • trial_administration_humans0
      • trial_bioequivalence_study1
      • trial_other0
      • trial_other_specify
      • trial_therapeutic_exploratory0
      • trial_therapeutic_confirmatory0
      • trial_therapeutic_use1
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n 1234</p>\n
      • other_details_explanation<p>\n explained</p>\n
      • other_details_regulatory_notapproved<p>\n reg</p>\n
      • other_details_regulatory_approved<p>\n reg</p>\n
      • other_details_regulatory_rejected<p>\n reg</p>\n
      • other_details_regulatory_halted
      • estimated_durationEsse ducimus possimus aut architecto esse in dolor illum tempor cillum
      • design_controlled_randomisedNo
      • design_controlled_openNo
      • design_controlled_single_blindNo
      • design_controlled_double_blindNo
      • design_controlled_parallel_groupNo
      • design_controlled_cross_overNo
      • design_controlled_otherYes
      • design_controlled_specifyNeque deserunt nostrud minima aut sed enim veniam odit assumenda officia
      • design_controlled_comparatorRepellendus Sed temporib
      • design_controlled_other_medicinalYes
      • design_controlled_placeboYes
      • design_controlled_medicinal_otherNo
      • design_controlled_medicinal_specify
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateYes
      • multiple_countriesYes
      • multiple_member_states772
      • number_of_sites961
      • multi_country_listDelectus suscipit e
      • data_monitoring_committeeNo
      • total_enrolment_per_siteDolor sint animi er
      • total_participants_worldwideCorrupti laudantium similique cupiditate nostrum rerum est vero laborum adipisicing
      • population_less_than_18_yearsYes
      • population_uteroNo
      • population_preterm_newbornNo
      • population_newbornYes
      • population_infant_and_toddlerNo
      • population_childrenNo
      • population_adolescentYes
      • population_above_18Yes
      • population_adultYes
      • population_elderlyNo
      • gender_female1
      • gender_male0
      • subjects_healthyNo
      • subjects_patientsNo
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionYes
      • subjects_pregnant_womenNo
      • subjects_nursing_womenYes
      • subjects_emergency_situationYes
      • subjects_incapable_consentYes
      • subjects_specifyVoluptatum perspicia
      • subjects_othersNo
      • subjects_others_specify
      • investigator1_given_nameBrent Mcknight
      • investigator1_middle_nameNicole Gross
      • investigator1_family_nameCharles Crane
      • investigator1_qualificationId adipisci commodo repellendus Dolor enim iste et quam deserunt id ut ullamco
      • investigator1_professional_addressQuia eius aut adipisicing rerum aut ad tempora necessitatibus cumque nisi at
      • investigator1_telephone+1 (795) 542-5315
      • investigator1_emaildudahabewy@mailinator.com
      • organisations_transferred_No
      • number_participantsVoluptatem ut nisi e
      • notification
      • approval_date19-11-2024
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted23-10-2024
      • unsubmitted0
      • initial_date_submitted(null)
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reasonApproved Here successfully
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice324112
      • modified2024-11-19 16:25:21
      • created2024-10-17 12:04:18
      • ai_content(null)
    • InvestigatorContact(array)
      • 0(array)
        • id72
        • application_id120
        • given_nameIrene Peterson
        • middle_nameMelinda Farrell
        • family_nameMarah Bush
        • qualificationId ipsa qui obcaecati sit iste eu reiciendis pariatur Possimus temporibus consequatur et culpa ad tenetur iusto inventore nihil labore
        • professional_addressCorporis ut quo libero ut ullam error
        • telephone+1 (524) 915-1935
        • emailpypamyhezu@mailinator.com
        • investigator_roleprincipal
        • created2024-10-17 12:49:37
        • modified2024-10-23 15:04:34
    • SiteDetail(array)
      • 0(array)
        • id1704
        • application_id120
        • county_id20
        • site_nameHarriet Battle
        • physical_addressQuae nulla sunt culpa beatae fugiat dolor quae labore similique in quae dignissimos a tempore ut tempore
        • contact_detailsP.O. Box 5325
        • contact_personNisi eum dolorem fugiat ullam dolore nemo laudantium aut autem natus similique numquam deserunt omnis quod officia
        • site_capacity(null)
        • misc(null)
        • created2024-10-17 12:49:37
        • modified2024-10-23 15:04:34
        • County(array)
          • id20
          • county_nameKirinyaga
          • created2012-06-15 10:24:22
          • modified2012-06-15 10:24:22
    • Sponsor(array)
      • 0(array)
        • id29
        • application_id120
        • sponsorFuga Aut qui est consequatur consectetur dolorem qui blanditiis saepe natus maiores ea repellendus Velit quia ullamco
        • sponsor_typeResearch Institution
        • contact_personNon corrupti reiciendis placeat elit aut voluptatibus optio labore excepteur
        • addressConsectetur ut ipsum quia quos magni
        • telephone_number+1 (367) 517-6326
        • fax_number+1 (961) 772-5694
        • cell_number+1 (895) 885-1686
        • email_addressrimumaxy@mailinator.com
        • created2024-10-17 12:49:37
        • modified2024-10-23 15:04:34
    • PublicAction(array)
      • labelApproved
      • date19-11-2024
  • 3(array)
    • Application(array)
      • id124
      • user_id26
      • application_id(null)
      • is_child0
      • trial_status_id4
      • trial_status_date2024-12-05 17:37:58
      • total_sites2
      • abstract_of_study<p>\n Testronimal Study Phase 2</p>\n
      • study_title<p>\n Testronimal Study Phase 2</p>\n
      • laymans_summary<p>\n Layman SUmmary</p>\n
      • short_titleTestronimal Study Phase 2
      • protocol_noECCT/24/11/01
      • reference_no
      • version_no1
      • date_of_protocol12-11-2024
      • study_drugTestronimal
      • disease_conditionCancer
      • product_type_biologicals1
      • product_type_proteins0
      • product_type_immunologicals1
      • product_type_vaccines0
      • product_type_hormones0
      • product_type_toxoid0
      • product_type_chemical1
      • product_type_medical_device0
      • product_type_chemical_nameEndo
      • product_type_medical_device_name
      • comparatorNo
      • comparator_name
      • comparator_registered
      • comparator_countries
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjayoma@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicanttest
      • declaration_date120-11-2024
      • declaration_principal_investigatortest
      • declaration_date220-11-2024
      • protocol_not_ai_generated0
      • placebo_presentNo
      • study_objectives<p>\n test</p>\n
      • principal_inclusion_criteria<p>\n test</p>\n
      • principal_exclusion_criteria<p>\n test</p>\n
      • primary_end_points<p>\n test</p>\n
      • scope_diagnosis0
      • scope_prophylaxis0
      • scope_therapy1
      • scope_safety0
      • scope_efficacy0
      • scope_pharmacokinetic0
      • scope_pharmacodynamic0
      • scope_bioequivalence0
      • scope_dose_response0
      • scope_pharmacogenetic1
      • scope_pharmacogenomic0
      • scope_pharmacoecomomic0
      • scope_others0
      • scope_others_specify
      • trial_human_pharmacology1
      • trial_administration_humans0
      • trial_bioequivalence_study1
      • trial_other0
      • trial_other_specify
      • trial_therapeutic_exploratory0
      • trial_therapeutic_confirmatory1
      • trial_therapeutic_use0
      • design_controlledNo
      • site_capacity(null)
      • staff_numbers<p>\n test</p>\n
      • other_details_explanation<p>\n test</p>\n
      • other_details_regulatory_notapproved<p>\n test</p>\n
      • other_details_regulatory_approved<p>\n test</p>\n
      • other_details_regulatory_rejected<p>\n test</p>\n
      • other_details_regulatory_halted<p>\n test</p>\n
      • estimated_duration1year
      • design_controlled_randomised
      • design_controlled_open
      • design_controlled_single_blind
      • design_controlled_double_blind
      • design_controlled_parallel_group
      • design_controlled_cross_over
      • design_controlled_other
      • design_controlled_specify
      • design_controlled_comparator
      • design_controlled_other_medicinal
      • design_controlled_placebo
      • design_controlled_medicinal_other
      • design_controlled_medicinal_specify
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateNo
      • multiple_countriesYes
      • multiple_member_states5
      • number_of_sites
      • multi_country_listtest
      • data_monitoring_committeeYes
      • total_enrolment_per_site2000
      • total_participants_worldwide2000000
      • population_less_than_18_yearsNo
      • population_uteroNo
      • population_preterm_newbornNo
      • population_newbornNo
      • population_infant_and_toddlerNo
      • population_childrenNo
      • population_adolescentNo
      • population_above_18Yes
      • population_adultYes
      • population_elderlyNo
      • gender_female1
      • gender_male0
      • subjects_healthyYes
      • subjects_patientsNo
      • subjects_vulnerable_populationsNo
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionNo
      • subjects_pregnant_womenNo
      • subjects_nursing_womenNo
      • subjects_emergency_situationNo
      • subjects_incapable_consentNo
      • subjects_specify
      • subjects_othersNo
      • subjects_others_specify
      • investigator1_given_nameInvestigating
      • investigator1_middle_name
      • investigator1_family_name Pharmacist
      • investigator1_qualificationMasters
      • investigator1_professional_address67
      • investigator1_telephone+254792837631
      • investigator1_emailinvest@gmail.com
      • organisations_transferred_No
      • number_participants100000
      • notification<p>\n test</p>\n
      • approval_date21-11-2024
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted20-11-2024
      • unsubmitted1
      • initial_date_submitted20-11-2024
      • admin_stopped1
      • admin_stopped_reasontest
      • approved2
      • approved_reasontest
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice330895
      • modified2025-01-14 12:41:33
      • created2024-11-20 09:09:12
      • ai_content(null)
    • InvestigatorContact(array)
      • 0(array)
        • id78
        • application_id124
        • given_nameJoel
        • middle_name
        • family_nameInvestigator
        • qualificationMasters
        • professional_addressP.O Box 381-3558,Accra
        • telephone+254790129837
        • emailjayoma@intellisoftkenya.com
        • investigator_roleprincipal
        • created2024-11-20 09:12:27
        • modified2025-01-14 12:21:23
    • SiteDetail(array)
      • 0(array)
        • id96
        • application_id124
        • county_id42
        • site_name
        • physical_address
        • contact_details
        • contact_person
        • site_capacity(null)
        • misc(null)
        • created2013-04-17 09:41:35
        • modified2025-01-14 12:21:23
        • County(array)
          • id42
          • county_nameKisumu
          • created2012-06-15 10:27:02
          • modified2012-06-15 10:27:02
    • Sponsor(array)
      • 0(array)
        • id31
        • application_id124
        • sponsorSponsor
        • sponsor_typeIndustry
        • contact_person
        • addressAddress
        • telephone_number+254782930397
        • fax_number
        • cell_number+254782930397
        • email_addressslow@gmail.com
        • created2024-11-20 09:12:27
        • modified2025-01-14 12:21:23
    • PublicAction(array)
      • labelApproved
      • date21-11-2024
  • 4(array)
    • Application(array)
      • id121
      • user_id29
      • application_id(null)
      • is_child0
      • trial_status_id10
      • trial_status_date(null)
      • total_sites4
      • abstract_of_study<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • study_title<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • laymans_summary<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • short_titleIusto obcaecati Nam dicta veli
      • protocol_noECCT/24/11/02
      • reference_no(null)
      • version_noConsectetur qui ipsam omnis eos et voluptas
      • date_of_protocol20-11-2015
      • study_drugEst esse ex reprehenderit aute laborum illo consectetur soluta atque dolor quia numquam odit delectus et aut placeat
      • disease_conditionEt officia qui consequuntur quisquam veritatis obcaecati sunt non sit dolorum quae
      • product_type_biologicals0
      • product_type_proteins1
      • product_type_immunologicals1
      • product_type_vaccines0
      • product_type_hormones0
      • product_type_toxoid1
      • product_type_chemical1
      • product_type_medical_device1
      • product_type_chemical_nameEagan Alston
      • product_type_medical_device_nameTanisha Rowland
      • comparatorYes
      • comparator_nameBrendan Blair
      • comparator_registeredAut enim quaerat consequatur s
      • comparator_countriesRerum quis ut veniam
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjkiprotich@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantSunt atque ipsum obcaecati commodo aspernatur fuga Voluptatem sed sequi cupidatat quo enim
      • declaration_date107-11-2024
      • declaration_principal_investigatorSit reprehenderit dicta beatae officia et magni deserunt ipsum in sint voluptates sed necessitatibus neque quis aspernatur esse ut
      • declaration_date214-11-2024
      • protocol_not_ai_generated0
      • placebo_presentYes
      • study_objectives<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • principal_inclusion_criteria<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • principal_exclusion_criteria<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • primary_end_points<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • scope_diagnosis1
      • scope_prophylaxis1
      • scope_therapy1
      • scope_safety0
      • scope_efficacy1
      • scope_pharmacokinetic0
      • scope_pharmacodynamic0
      • scope_bioequivalence0
      • scope_dose_response0
      • scope_pharmacogenetic0
      • scope_pharmacogenomic1
      • scope_pharmacoecomomic0
      • scope_others1
      • scope_others_specifyLorem voluptatem Ab
      • trial_human_pharmacology1
      • trial_administration_humans1
      • trial_bioequivalence_study1
      • trial_other1
      • trial_other_specifySimilique tempore c
      • trial_therapeutic_exploratory1
      • trial_therapeutic_confirmatory1
      • trial_therapeutic_use1
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • other_details_explanation<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • other_details_regulatory_notapproved<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • other_details_regulatory_approved<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • other_details_regulatory_rejected<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • other_details_regulatory_halted<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • estimated_duration3
      • design_controlled_randomisedNo
      • design_controlled_openNo
      • design_controlled_single_blindYes
      • design_controlled_double_blindNo
      • design_controlled_parallel_groupYes
      • design_controlled_cross_overNo
      • design_controlled_otherYes
      • design_controlled_specifyEum labore saepe rem quia sint dolore porro magni nihil facilis doloribus sint ipsa et officia distinctio Aut
      • design_controlled_comparatorBlanditiis quaerat est ex
      • design_controlled_other_medicinalYes
      • design_controlled_placeboNo
      • design_controlled_medicinal_otherNo
      • design_controlled_medicinal_specify
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateNo
      • multiple_countriesYes
      • multiple_member_states4
      • number_of_sites
      • multi_country_listHarum hic tempora ne
      • data_monitoring_committeeYes
      • total_enrolment_per_siteNon ex beatae a dele
      • total_participants_worldwideExcepteur maxime nisi voluptatem minim ad quisquam harum dolore doloribus quia sunt consequatur Perspiciatis doloribus sed
      • population_less_than_18_yearsYes
      • population_uteroNo
      • population_preterm_newbornYes
      • population_newbornYes
      • population_infant_and_toddlerNo
      • population_childrenNo
      • population_adolescentNo
      • population_above_18Yes
      • population_adultNo
      • population_elderlyYes
      • gender_female1
      • gender_male0
      • subjects_healthyNo
      • subjects_patientsNo
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionYes
      • subjects_pregnant_womenNo
      • subjects_nursing_womenNo
      • subjects_emergency_situationNo
      • subjects_incapable_consentNo
      • subjects_specify
      • subjects_othersYes
      • subjects_others_specifyExercitation perspic
      • investigator1_given_nameRachel Hewitt
      • investigator1_middle_nameKylynn Townsend
      • investigator1_family_nameOctavia Acosta
      • investigator1_qualificationDolores quae ut corrupti voluptatem in aliquip animi esse aliqua Dicta sapiente ipsam debitis impedit nobis
      • investigator1_professional_addressVel aut quis in consectetur incidunt placeat sint consectetur sint dolores commodi
      • investigator1_telephone+1 (618) 138-4296
      • investigator1_emailbezic@mailinator.com
      • organisations_transferred_Yes
      • number_participantsSuscipit adipisicing
      • notification<p>\n Clinical trials are research studies conducted with human participants to evaluate the safety, effectiveness, and potential side effects of medical interventions, such as new drugs, devices, or therapies. These trials are essential for advancing medical knowledge and ensuring treatments meet rigorous standards. By following a structured approach, clinical trials provide a systematic way to assess new interventions before they are widely adopted in healthcare.</p>\n<p>\n The process of clinical trials typically progresses through multiple phases. Early phases focus on determining safety and optimal dosing in smaller groups, while later phases assess the efficacy and broader application of the intervention in larger populations. This phased approach ensures that each stage addresses specific scientific and medical questions, gradually building a comprehensive understanding of the intervention's impact.</p>\n<p>\n Ethical guidelines and scientific rigor are crucial in clinical trials to protect participants and maintain public trust. Researchers adhere to principles like informed consent and beneficence while ensuring trials are inclusive and unbiased. By bridging the gap between laboratory research and real-world medical practice, clinical trials play a critical role in improving healthcare outcomes globally.</p>\n
      • approval_date29-11-2024
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted20-11-2024
      • unsubmitted0
      • initial_date_submitted(null)
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reasonTest
      • approved_date(null)
      • final_report<p>\n test sample</p>\n
      • implication_results<p>\n sample</p>\n
      • quantity_imported2
      • quantity_dispensed3
      • quantity_destroyed4
      • quantity_exported1
      • balance_site2
      • final_date2025-08-05
      • ecitizen_invoice324265
      • modified2025-08-05 08:08:23
      • created2024-10-18 08:02:13
      • ai_content(null)
    • InvestigatorContact(array)
      • 0(array)
        • id79
        • application_id121
        • given_nameLinus Sexton
        • middle_nameOri Hill
        • family_nameJacob Mckay
        • qualificationIllum doloribus soluta numquam omnis elit quibusdam non
        • professional_addressAliquam fugiat qui officia veniam excepturi et nisi neque enim aliquip tempora
        • telephone+1 (188) 739-1402
        • emailmipaj@mailinator.com
        • investigator_roleprincipal
        • created2024-11-20 09:47:01
        • modified2024-11-20 10:15:06
    • SiteDetail(array)
      • 0(array)
        • id94
        • application_id121
        • county_id(null)
        • site_name
        • physical_address
        • contact_details
        • contact_person
        • site_capacity(null)
        • misc(null)
        • created2013-04-16 14:25:04
        • modified2024-11-20 10:15:06
        • County(empty)
    • Sponsor(array)
      • 0(array)
        • id32
        • application_id121
        • sponsorAnim obcaecati dolorem cillum qui nemo in vitae ea veritatis
        • sponsor_typeIndustry
        • contact_personFugiat corporis inventore non commodo nesciunt ut non doloremque optio voluptates minima recusandae Veritatis reprehenderit velit commodo
        • addressAutem odio eaque quia est blanditiis reiciendis commodi et adipisicing enim voluptate
        • telephone_number+1 (343) 625-7251
        • fax_number+1 (936) 324-2944
        • cell_number+1 (942) 698-1737
        • email_addressvugit@mailinator.com
        • created2024-11-20 09:47:01
        • modified2024-11-20 10:15:06
    • PublicAction(array)
      • labelApproved
      • date29-11-2024
  • 5(array)
    • Application(array)
      • id125
      • user_id29
      • application_id(null)
      • is_child0
      • trial_status_id10
      • trial_status_date(null)
      • total_sites5
      • abstract_of_study<p>\n sample</p>\n
      • study_title<p>\n sample</p>\n
      • laymans_summary<p>\n sample</p>\n
      • short_titleEt eius sit aut et fugiat adi
      • protocol_noECCT/24/12/01
      • reference_no(null)
      • version_noDolorem veniam pariatur Consequat Numquam et digniss
      • date_of_protocol01-12-2024
      • study_drugId debitis rerum natus molestiae reprehenderit doloremque recusandae Ratione perspiciatis velit minim delectus similique suscipit fugiat
      • disease_conditionTempor numquam voluptas amet aut tempore repellendus Magni pariatur
      • product_type_biologicals0
      • product_type_proteins0
      • product_type_immunologicals1
      • product_type_vaccines0
      • product_type_hormones1
      • product_type_toxoid0
      • product_type_chemical0
      • product_type_medical_device1
      • product_type_chemical_nameStone Atkins
      • product_type_medical_device_nameAnthony Lawrence
      • comparatorNo
      • comparator_nameSydnee Woods
      • comparator_registeredEt sint officia eos asperiore
      • comparator_countriesVel anim voluptatem
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjkiprotich@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantQuo tenetur ex ut tempora consequatur rerum qui amet officiis sed molestiae fuga Quibusdam velit eu soluta voluptates amet
      • declaration_date117-12-2024
      • declaration_principal_investigatorSint explicabo Sint quos omnis quia aliquid non ullamco ipsum quia dignissimos qui et consequat Voluptatum cupidatat aut
      • declaration_date217-12-2024
      • protocol_not_ai_generated0
      • placebo_presentYes
      • study_objectives<p>\n sample</p>\n
      • principal_inclusion_criteria<p>\n sample</p>\n
      • principal_exclusion_criteria<p>\n sample</p>\n
      • primary_end_points<p>\n sample</p>\n
      • scope_diagnosis1
      • scope_prophylaxis0
      • scope_therapy0
      • scope_safety1
      • scope_efficacy0
      • scope_pharmacokinetic0
      • scope_pharmacodynamic1
      • scope_bioequivalence0
      • scope_dose_response0
      • scope_pharmacogenetic0
      • scope_pharmacogenomic1
      • scope_pharmacoecomomic0
      • scope_others0
      • scope_others_specify
      • trial_human_pharmacology0
      • trial_administration_humans0
      • trial_bioequivalence_study1
      • trial_other0
      • trial_other_specify
      • trial_therapeutic_exploratory1
      • trial_therapeutic_confirmatory0
      • trial_therapeutic_use0
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n sample</p>\n
      • other_details_explanation<p>\n sample</p>\n
      • other_details_regulatory_notapproved<p>\n sample</p>\n
      • other_details_regulatory_approved<p>\n sample</p>\n
      • other_details_regulatory_rejected<p>\n sample</p>\n
      • other_details_regulatory_halted<p>\n sample</p>\n
      • estimated_duration4
      • design_controlled_randomisedNo
      • design_controlled_openYes
      • design_controlled_single_blindNo
      • design_controlled_double_blindNo
      • design_controlled_parallel_groupYes
      • design_controlled_cross_overYes
      • design_controlled_otherNo
      • design_controlled_specify
      • design_controlled_comparatorRecusandae Fuga Ut est
      • design_controlled_other_medicinalYes
      • design_controlled_placeboYes
      • design_controlled_medicinal_otherNo
      • design_controlled_medicinal_specify
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateYes
      • multiple_countriesNo
      • multiple_member_states
      • number_of_sites543
      • multi_country_list
      • data_monitoring_committeeYes
      • total_enrolment_per_siteQuidem in duis fugia
      • total_participants_worldwideSit ut quae amet at tempor et commodo voluptas quod neque adipisci nemo labore Nam officia ut commodi
      • population_less_than_18_yearsYes
      • population_uteroNo
      • population_preterm_newbornNo
      • population_newbornNo
      • population_infant_and_toddlerNo
      • population_childrenNo
      • population_adolescentYes
      • population_above_18Yes
      • population_adultNo
      • population_elderlyNo
      • gender_female1
      • gender_male0
      • subjects_healthyYes
      • subjects_patientsYes
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingYes
      • subjects_women_using_contraceptionNo
      • subjects_pregnant_womenNo
      • subjects_nursing_womenYes
      • subjects_emergency_situationYes
      • subjects_incapable_consentYes
      • subjects_specifyFacilis quia totam u
      • subjects_othersYes
      • subjects_others_specifyNulla ipsam dolore i
      • investigator1_given_nameDominique Solomon
      • investigator1_middle_nameHyacinth Bond
      • investigator1_family_nameIndira Shaffer
      • investigator1_qualificationRerum adipisicing magnam qui rerum nemo dicta eligendi quis inventore provident accusantium aperiam ipsum enim qui asperiores
      • investigator1_professional_addressSit aut at tenetur enim culpa
      • investigator1_telephone+1 (956) 653-5189
      • investigator1_emailpydekizef@mailinator.com
      • organisations_transferred_Yes
      • number_participantsVoluptatum aliqua I
      • notification<p>\n sample</p>\n
      • approval_date17-12-2024
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted17-12-2024
      • unsubmitted1
      • initial_date_submitted17-12-2024
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reason
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice(null)
      • modified2025-01-07 08:39:12
      • created2024-11-29 09:22:21
      • ai_content(null)
    • InvestigatorContact(array)
      • 0(array)
        • id81
        • application_id125
        • given_nameLawrence Jennings
        • middle_nameAladdin Powers
        • family_nameElton Delgado
        • qualificationUllam deleniti aliqua Excepteur nisi id dolorum vel ipsum a irure repudiandae molestias aut quos suscipit et dolore reprehenderit eu
        • professional_addressUt facere ea aliquam eveniet
        • telephone+1 (328) 771-3449
        • emailxycuqez@mailinator.com
        • investigator_roleprincipal
        • created2024-12-17 08:32:23
        • modified2025-01-06 11:48:30
    • SiteDetail(array)
      • 0(array)
        • id1705
        • application_id125
        • county_id25
        • site_nameChastity Horne
        • physical_addressA alias veritatis aute asperiores voluptatem anim id irure veniam qui
        • contact_detailsPO Box 91937
        • contact_personAtque esse sint consectetur qui tempor dicta sit illo id consectetur illo qui quo soluta
        • site_capacity(null)
        • misc(null)
        • created2024-12-17 08:32:23
        • modified2025-01-06 11:48:30
        • County(array)
          • id25
          • county_nameSamburu
          • created2012-06-15 10:24:58
          • modified2012-06-15 10:24:58
    • Sponsor(array)
      • 0(array)
        • id33
        • application_id125
        • sponsorDolore sunt reprehenderit voluptas commodi asperiores
        • sponsor_typeIndustry
        • contact_personAd consequatur nulla aut quo explicabo Eligendi similique ex cum sed voluptas sint sit dolorem nulla asperiores suscipit
        • addressQuis ipsa voluptatum non officia nisi minus officia est et
        • telephone_number+1 (498) 749-6935
        • fax_number+1 (547) 888-9241
        • cell_number+1 (941) 425-9332
        • email_addresscidesy@mailinator.com
        • created2024-12-17 08:32:23
        • modified2025-01-06 11:48:30
    • PublicAction(array)
      • labelApproved
      • date17-12-2024
  • 6(array)
    • Application(array)
      • id127
      • user_id26
      • application_id(null)
      • is_child0
      • trial_status_id7
      • trial_status_date(null)
      • total_sites3
      • abstract_of_study<p>\n test</p>\n
      • study_title<p>\n Laborum Doloribus illo impedi</p>\n
      • laymans_summary<p>\n test</p>\n
      • short_titleLaborum Doloribus illo impedi
      • protocol_noECCT/25/01/01
      • reference_no
      • version_noEt duis deserunt tempor blanditiis omnis cum distinctio
      • date_of_protocol15-01-1977
      • study_drugOccaecat quidem sunt officia adipisci aperiam reprehenderit illo error culpa atque ut voluptas sit vero
      • disease_conditionImpedit eaque facilis dignissimos magni dolorem sit dolore in quia modi cumque dicta
      • product_type_biologicals0
      • product_type_proteins0
      • product_type_immunologicals1
      • product_type_vaccines0
      • product_type_hormones1
      • product_type_toxoid0
      • product_type_chemical0
      • product_type_medical_device1
      • product_type_chemical_nameAmela Wiley
      • product_type_medical_device_nameMiranda Fry
      • comparatorYes
      • comparator_nameHolmes Tanner
      • comparator_registeredEnim aperiam incidunt est ut
      • comparator_countriesDeserunt eiusmod ver
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressqimuvo@mailinator.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement0
      • declaration_applicantUnde lorem aut expedita sed assumenda sint qui cupiditate
      • declaration_date108-12-2013
      • declaration_principal_investigatorError tempor odit dicta aute perferendis autem cum doloribus omnis odio quaerat nihil reiciendis quasi eos minima itaque
      • declaration_date207-01-2025
      • protocol_not_ai_generated0
      • placebo_presentYes
      • study_objectives<p>\n test</p>\n
      • principal_inclusion_criteria<p>\n test</p>\n
      • principal_exclusion_criteria<p>\n test</p>\n
      • primary_end_points<p>\n test</p>\n
      • scope_diagnosis1
      • scope_prophylaxis0
      • scope_therapy1
      • scope_safety1
      • scope_efficacy0
      • scope_pharmacokinetic0
      • scope_pharmacodynamic1
      • scope_bioequivalence0
      • scope_dose_response0
      • scope_pharmacogenetic0
      • scope_pharmacogenomic1
      • scope_pharmacoecomomic0
      • scope_others0
      • scope_others_specify
      • trial_human_pharmacology1
      • trial_administration_humans0
      • trial_bioequivalence_study1
      • trial_other0
      • trial_other_specify
      • trial_therapeutic_exploratory1
      • trial_therapeutic_confirmatory1
      • trial_therapeutic_use0
      • design_controlledNo
      • site_capacity(null)
      • staff_numbers<p>\n test</p>\n
      • other_details_explanation<p>\n test</p>\n
      • other_details_regulatory_notapproved<p>\n tets</p>\n
      • other_details_regulatory_approved<p>\n test</p>\n
      • other_details_regulatory_rejected<p>\n tets</p>\n
      • other_details_regulatory_halted<p>\n test</p>\n
      • estimated_durationEx qui assumenda laudantium eos dolor voluptatem Quaerat vero ut ex voluptatem corporis neque laborum Irure
      • design_controlled_randomised
      • design_controlled_open
      • design_controlled_single_blind
      • design_controlled_double_blind
      • design_controlled_parallel_group
      • design_controlled_cross_over
      • design_controlled_other
      • design_controlled_specify
      • design_controlled_comparator
      • design_controlled_other_medicinal
      • design_controlled_placebo
      • design_controlled_medicinal_other
      • design_controlled_medicinal_specify
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateYes
      • multiple_countriesYes
      • multiple_member_states20
      • number_of_sites2
      • multi_country_listEos aute voluptatem
      • data_monitoring_committeeNo
      • total_enrolment_per_site200
      • total_participants_worldwideVoluptatem incididunt nostrud sint error nobis itaque nisi enim
      • population_less_than_18_yearsYes
      • population_uteroNo
      • population_preterm_newbornYes
      • population_newbornYes
      • population_infant_and_toddlerYes
      • population_childrenYes
      • population_adolescentNo
      • population_above_18Yes
      • population_adultYes
      • population_elderlyNo
      • gender_female0
      • gender_male1
      • subjects_healthyYes
      • subjects_patientsNo
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionYes
      • subjects_pregnant_womenYes
      • subjects_nursing_womenUnclear
      • subjects_emergency_situationYes
      • subjects_incapable_consentYes
      • subjects_specifyLabore quae cum qui
      • subjects_othersYes
      • subjects_others_specifyVoluptate qui sed al
      • investigator1_given_nameRemedios Steele
      • investigator1_middle_nameTaShya Moore
      • investigator1_family_nameBrady Key
      • investigator1_qualificationEveniet laudantium doloremque provident illo maiores asperiores animi totam reiciendis corporis est
      • investigator1_professional_addressVoluptatibus voluptates nemo sit et lorem
      • investigator1_telephone+1 (974) 807-5529
      • investigator1_emailcuvicenuwy@mailinator.com
      • organisations_transferred_No
      • number_participants20000
      • notification<p>\n test</p>\n
      • approval_date07-01-2025
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted07-01-2025
      • unsubmitted1
      • initial_date_submitted07-01-2025
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reasontest
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice343770
      • modified2025-02-18 08:53:19
      • created2025-01-06 15:07:01
      • ai_content(null)
    • InvestigatorContact(array)
      • 0(array)
        • id84
        • application_id127
        • given_nameAidan Madden
        • middle_nameYeo Christensen
        • family_nameNola Nielsen
        • qualificationNecessitatibus sed amet quia mollitia quia magnam nostrum elit vel et repellendus Culpa
        • professional_addressConsectetur iure ea blanditiis illo facilis sed magna elit non alias
        • telephone+1 (375) 498-2766
        • emailtomap@mailinator.com
        • investigator_roleprincipal
        • created2025-01-06 15:08:18
        • modified2025-02-06 14:33:08
    • SiteDetail(array)
      • 0(array)
        • id129
        • application_id127
        • county_id38
        • site_nameIsadora Long
        • physical_addressQuas aut corporis in ea incidunt eligendi voluptas tempora sed ex et eiusmod illum ipsam quibusdam delectus officia exercitationem velit
        • contact_detailsP.O. Box 5
        • contact_personAnimi et porro velit excepturi vitae lorem excepturi iusto est labore excepturi ipsa sunt ad beatae velit
        • site_capacity(null)
        • misc(null)
        • created2013-06-27 11:37:16
        • modified2025-02-06 14:33:08
        • County(array)
          • id38
          • county_nameVihiga
          • created2012-06-15 10:26:37
          • modified2012-06-15 10:26:37
    • Sponsor(array)
      • 0(array)
        • id34
        • application_id127
        • sponsorFugit nulla amet numquam veniam qui minim ratione ducimus voluptatem Eos molestiae obcaecati est repudiandae aut id Nam enim ut
        • sponsor_typeResearch Institution
        • contact_personQuasi voluptas voluptate veritatis quis
        • addressVoluptatem Sit eum voluptas nobis aliqua Nostrud minus officia voluptatum eveniet vel lorem aperiam cupidatat
        • telephone_number+1 (924) 838-9502
        • fax_number+1 (461) 834-7154
        • cell_number+1 (976) 269-8435
        • email_addressgopokilos@mailinator.com
        • created2025-01-06 15:08:18
        • modified2025-02-06 14:33:08
    • PublicAction(array)
      • labelApproved
      • date07-01-2025
  • 7(array)
    • Application(array)
      • id128
      • user_id29
      • application_id(null)
      • is_child0
      • trial_status_id10
      • trial_status_date(null)
      • total_sites2
      • abstract_of_study<p>\n samlpe</p>\n
      • study_title<p>\n Jan 7th</p>\n
      • laymans_summary<p>\n sample Laymans Summary</p>\n
      • short_titleQuis quaerat anim voluptatem p
      • protocol_noECCT/25/01/02
      • reference_no
      • version_noOdit nulla saepe ut possimus esse maiores
      • date_of_protocol02-01-2025
      • study_drugSed velit rerum vel reprehenderit aut aliquid
      • disease_conditionEst excepteur odio quasi aut accusantium fugiat iste ab non aut impedit minima quidem dolorum id aut aliquip dolore
      • product_type_biologicals1
      • product_type_proteins1
      • product_type_immunologicals1
      • product_type_vaccines0
      • product_type_hormones1
      • product_type_toxoid1
      • product_type_chemical1
      • product_type_medical_device1
      • product_type_chemical_nameIlliana Smith
      • product_type_medical_device_nameKennedy Cote
      • comparatorYes
      • comparator_nameMyra Anderson
      • comparator_registeredVoluptas consequat Veniam ar
      • comparator_countriesConsequat Voluptati
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjkiprotich@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantVoluptate necessitatibus aliqua Labore ea deserunt eu amet excepturi
      • declaration_date102-01-2025
      • declaration_principal_investigatorSint voluptates quasi ipsum asperiores nisi quae eum deserunt quod quaerat saepe
      • declaration_date203-01-2025
      • protocol_not_ai_generated0
      • placebo_presentYes
      • study_objectives<p>\n sample</p>\n
      • principal_inclusion_criteria<p>\n sample</p>\n
      • principal_exclusion_criteria<p>\n sample</p>\n
      • primary_end_points<p>\n sample</p>\n
      • scope_diagnosis1
      • scope_prophylaxis1
      • scope_therapy1
      • scope_safety0
      • scope_efficacy1
      • scope_pharmacokinetic1
      • scope_pharmacodynamic1
      • scope_bioequivalence0
      • scope_dose_response0
      • scope_pharmacogenetic1
      • scope_pharmacogenomic1
      • scope_pharmacoecomomic1
      • scope_others1
      • scope_others_specifyMinima proident aut
      • trial_human_pharmacology1
      • trial_administration_humans1
      • trial_bioequivalence_study0
      • trial_other0
      • trial_other_specifyIn temporibus volupt
      • trial_therapeutic_exploratory0
      • trial_therapeutic_confirmatory0
      • trial_therapeutic_use1
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n sample</p>\n
      • other_details_explanation<p>\n sample</p>\n
      • other_details_regulatory_notapproved<p>\n sample</p>\n
      • other_details_regulatory_approved<p>\n sample</p>\n
      • other_details_regulatory_rejected<p>\n sample</p>\n
      • other_details_regulatory_halted<p>\n sample</p>\n
      • estimated_durationVoluptatem accusamus similique quia velit quidem ipsa mollit vitae omnis odio pariatur Voluptas et possimus illum tempora id ut maiores
      • design_controlled_randomisedNo
      • design_controlled_openNo
      • design_controlled_single_blindNo
      • design_controlled_double_blindYes
      • design_controlled_parallel_groupNo
      • design_controlled_cross_overYes
      • design_controlled_otherYes
      • design_controlled_specifyEt excepteur do velit illum blanditiis vel
      • design_controlled_comparatorEst deserunt ipsa harum
      • design_controlled_other_medicinalYes
      • design_controlled_placeboNo
      • design_controlled_medicinal_otherYes
      • design_controlled_medicinal_specifyEst elit ipsa dolorem debitis atque quod mollitia exercitationem elit tempor totam alias
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateYes
      • multiple_countriesYes
      • multiple_member_states141
      • number_of_sites261
      • multi_country_listSint dolore earum i
      • data_monitoring_committeeNo
      • total_enrolment_per_siteHic et dolor placeat
      • total_participants_worldwideDolor ut rem nobis perspiciatis qui necessitatibus facere modi deleniti ut rerum qui atque cupiditate enim quo tempora totam
      • population_less_than_18_yearsYes
      • population_uteroYes
      • population_preterm_newbornYes
      • population_newbornYes
      • population_infant_and_toddlerNo
      • population_childrenNo
      • population_adolescentNo
      • population_above_18Yes
      • population_adultYes
      • population_elderlyNo
      • gender_female1
      • gender_male1
      • subjects_healthyYes
      • subjects_patientsYes
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionNo
      • subjects_pregnant_womenYes
      • subjects_nursing_womenUnclear
      • subjects_emergency_situationYes
      • subjects_incapable_consentYes
      • subjects_specifyRatione optio accus
      • subjects_othersYes
      • subjects_others_specifyIncididunt dolores i
      • investigator1_given_nameCarissa Haley
      • investigator1_middle_nameHashim Ellison
      • investigator1_family_nameRuby Conway
      • investigator1_qualificationCorrupti id et velit aperiam sunt eligendi do minim illum et eos tenetur autem modi non et dolore magna eius
      • investigator1_professional_addressCulpa in qui rerum mollit voluptatem quisquam rerum esse dolore libero non aut inventore dicta quis voluptatem molestiae
      • investigator1_telephone+1 (852) 478-7381
      • investigator1_emailpinewideji@mailinator.com
      • organisations_transferred_Yes
      • number_participantsEx eu est et quos
      • notification<p>\n sample</p>\n
      • approval_date07-01-2025
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted17-02-2025
      • unsubmitted1
      • initial_date_submitted17-02-2025
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reasonSample
      • approved_date(null)
      • final_report<p>\n Sample Executive</p>\n
      • implication_results<p>\n Sample Implications of the results on current practice</p>\n
      • quantity_imported10
      • quantity_dispensed13
      • quantity_destroyed13
      • quantity_exported12
      • balance_site15
      • final_date2025-07-11
      • ecitizen_invoice344039
      • modified2025-07-11 17:18:26
      • created2025-01-07 09:26:39
      • ai_content(null)
    • InvestigatorContact(array)
      • 0(array)
        • id86
        • application_id128
        • given_nameBaker Spears
        • middle_nameCassandra Castaneda
        • family_nameLane Robbins
        • qualificationBlanditiis consequatur recusandae Natus libero quis
        • professional_addressOfficiis illo laborum cupiditate do dolores omnis in sint quisquam nostrud fuga Perspiciatis nemo
        • telephone+1 (993) 659-9852
        • emailpenoguje@mailinator.com
        • investigator_roleprincipal
        • created2025-01-07 09:33:40
        • modified2025-02-17 10:51:23
    • SiteDetail(array)
      • 0(array)
        • id1706
        • application_id128
        • county_id43
        • site_nameDaquan Lane
        • physical_addressUt qui enim recusandae Unde qui esse beatae autem quia velit
        • contact_detailsPO Box 5703
        • contact_personVeniam optio vel modi repellendus
        • site_capacity(null)
        • misc(null)
        • created2025-01-07 09:33:40
        • modified2025-02-17 10:51:23
        • County(array)
          • id43
          • county_nameHoma Bay
          • created2012-06-15 10:27:10
          • modified2012-06-15 10:27:10
    • Sponsor(array)
      • 0(array)
        • id35
        • application_id128
        • sponsorAut voluptatum est ab voluptas tempore aut et voluptas dolore architecto ad suscipit saepe omnis quaerat
        • sponsor_typeLocal Kenyan Investigator
        • contact_personQuas ut consectetur ratione est tempor quo odio iure esse occaecat eius suscipit explicabo Quasi sit
        • addressExcepteur distinctio Enim vitae reiciendis aut aliquid incididunt repudiandae nesciunt beatae adipisci
        • telephone_number+1 (731) 766-1698
        • fax_number+1 (493) 753-7389
        • cell_number+1 (179) 791-1499
        • email_addresscovoginoby@mailinator.com
        • created2025-01-07 09:33:40
        • modified2025-02-17 10:51:23
    • PublicAction(array)
      • labelApproved
      • date07-01-2025
  • 8(array)
    • Application(array)
      • id158
      • user_id86
      • application_id118
      • is_child1
      • trial_status_id7
      • trial_status_date(null)
      • total_sites5
      • abstract_of_study<p>\n <em>Background:</em> The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.</p>\n<p>\n <em>Objective:</em> This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of <em>Virunex-3</em>, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.</p>\n<p>\n <em>Methods:</em> A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either <em>Virunex-3</em> (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.</p>\n<p>\n <em>Expected Outcomes:</em> The study aims to determine whether <em>Virunex-3</em> can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.</p>\n<p>\n <em>Conclusion:</em> By assessing both the effectiveness and safety of <em>Virunex-3</em>, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.</p>\n
      • study_title<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • laymans_summary<p>\n This study is designed to test a new antiviral medication called <em>Virunex-3</em> to see if it can help people recover faster from an illness caused by a newly identified virus called <em>Novacov-24</em>. Participants in the study will either receive <em>Virunex-3</em> or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if <em>Virunex-3</em> can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.</p>\n
      • short_titleVirunex-3 Trial for Novacov-24
      • protocol_noECCT/25/01/09 - A
      • reference_no1234redwsqa
      • version_nov1
      • date_of_protocol01-01-2025
      • study_drugVirunex-3
      • disease_conditionNovacov-24 Virus Infection
      • product_type_biologicals1
      • product_type_proteins0
      • product_type_immunologicals1
      • product_type_vaccines0
      • product_type_hormones0
      • product_type_toxoid0
      • product_type_chemical0
      • product_type_medical_device0
      • product_type_chemical_name
      • product_type_medical_device_name
      • comparatorNo
      • comparator_name
      • comparator_registered
      • comparator_countries
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjkiprotich@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
      • declaration_date110-01-2025
      • declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
      • declaration_date209-01-2025
      • protocol_not_ai_generated0
      • placebo_presentYes
      • study_objectives<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • principal_inclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • principal_exclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • primary_end_points<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • scope_diagnosis1
      • scope_prophylaxis0
      • scope_therapy0
      • scope_safety0
      • scope_efficacy0
      • scope_pharmacokinetic0
      • scope_pharmacodynamic1
      • scope_bioequivalence0
      • scope_dose_response1
      • scope_pharmacogenetic0
      • scope_pharmacogenomic0
      • scope_pharmacoecomomic1
      • scope_others1
      • scope_others_specifyIn odit voluptate fu
      • trial_human_pharmacology0
      • trial_administration_humans1
      • trial_bioequivalence_study0
      • trial_other1
      • trial_other_specifyVoluptas veniam ut
      • trial_therapeutic_exploratory0
      • trial_therapeutic_confirmatory1
      • trial_therapeutic_use1
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_explanation<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_notapproved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_approved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_rejected
      • other_details_regulatory_halted
      • estimated_durationTempore id architecto quaerat ad vel
      • design_controlled_randomisedNo
      • design_controlled_openYes
      • design_controlled_single_blindNo
      • design_controlled_double_blindYes
      • design_controlled_parallel_groupNo
      • design_controlled_cross_overYes
      • design_controlled_otherYes
      • design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
      • design_controlled_comparatorAut qui perspiciatis rei
      • design_controlled_other_medicinalNo
      • design_controlled_placeboNo
      • design_controlled_medicinal_otherYes
      • design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateYes
      • multiple_countriesNo
      • multiple_member_states
      • number_of_sites6
      • multi_country_list
      • data_monitoring_committeeNo
      • total_enrolment_per_siteVitae voluptatem se
      • total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
      • population_less_than_18_yearsYes
      • population_uteroYes
      • population_preterm_newbornYes
      • population_newbornYes
      • population_infant_and_toddlerNo
      • population_childrenYes
      • population_adolescentNo
      • population_above_18Yes
      • population_adultNo
      • population_elderlyNo
      • gender_female1
      • gender_male0
      • subjects_healthyNo
      • subjects_patientsYes
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionYes
      • subjects_pregnant_womenNo
      • subjects_nursing_womenYes
      • subjects_emergency_situationNo
      • subjects_incapable_consentYes
      • subjects_specifyId tempora omnis vol
      • subjects_othersYes
      • subjects_others_specifyUllam laborum Eos
      • investigator1_given_nameIlliana Ferguson
      • investigator1_middle_nameAllen Fox
      • investigator1_family_nameYolanda Rivera
      • investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
      • investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
      • investigator1_telephone+1 (621) 831-1153
      • investigator1_emailqeryrilu@mailinator.com
      • organisations_transferred_Yes
      • number_participantsMinim dolor commodo
      • notification
      • approval_date13-01-2025
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted22-01-2025
      • unsubmitted1
      • initial_date_submitted22-01-2025
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reasonThis is approved
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice324073
      • modified2025-02-13 08:07:31
      • created2025-01-22 10:39:23
      • ai_content(null)
    • InvestigatorContact(array)
      • 0(array)
        • id91
        • application_id158
        • given_nameHiroko Lewis
        • middle_nameTatyana Medina
        • family_nameCastor Gallagher
        • qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
        • professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
        • telephone+1 (322) 766-3057
        • emailtipyhuqo@mailinator.com
        • investigator_roleprincipal
        • created2025-01-13 12:13:08
        • modified2025-02-13 08:07:31
    • SiteDetail(array)
      • 0(array)
        • id128
        • application_id158
        • county_id42
        • site_nameMiranda Alvarez
        • physical_addressAut ad quasi commodi non sint libero enim eos consequatur corrupti harum non
        • contact_detailsP.O. Box 86856
        • contact_personVoluptatibus molestias eligendi non repudiandae quis ipsa minim quia nostrum ut nisi possimus veniam
        • site_capacity(null)
        • misc(null)
        • created2013-06-27 10:49:32
        • modified2025-02-13 08:07:31
        • County(array)
          • id42
          • county_nameKisumu
          • created2012-06-15 10:27:02
          • modified2012-06-15 10:27:02
    • Sponsor(array)
      • 0(array)
        • id39
        • application_id158
        • sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
        • sponsor_typeLocal Kenyan Investigator
        • contact_personDolorem mollitia id quis provident error voluptatem voluptate
        • addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
        • telephone_number+1 (666) 325-1183
        • fax_number+1 (314) 248-5575
        • cell_number+1 (134) 102-6236
        • email_addresstuhokelyh@mailinator.com
        • created2025-01-13 12:13:08
        • modified2025-02-13 08:07:31
    • PublicAction(array)
      • labelApproved
      • date13-01-2025
  • 9(array)
    • Application(array)
      • id159
      • user_id86
      • application_id118
      • is_child1
      • trial_status_id(null)
      • trial_status_date(null)
      • total_sites5
      • abstract_of_study<p>\n <em>Background:</em> The Novacov-24 virus, a newly identified respiratory pathogen, has raised global health concerns due to its rapid spread and potential for severe illness. Effective antiviral treatments are urgently needed to reduce symptom severity, prevent complications, and lower hospitalization rates.</p>\n<p>\n <em>Objective:</em> This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of <em>Virunex-3</em>, a novel antiviral agent, in reducing the severity and duration of symptoms in patients infected with the Novacov-24 virus.</p>\n<p>\n <em>Methods:</em> A total of 500 adult participants with confirmed Novacov-24 infection will be enrolled. Participants will be randomly assigned to receive either <em>Virunex-3</em> (100 mg orally, once daily for 7 days) or a placebo. Primary outcomes will include the reduction of viral load and symptom resolution within 7 days. Secondary outcomes will assess hospitalization rates, need for mechanical ventilation, and mortality. Adverse events and treatment safety will also be monitored.</p>\n<p>\n <em>Expected Outcomes:</em> The study aims to determine whether <em>Virunex-3</em> can effectively reduce symptoms and improve patient recovery while ensuring safety. If successful, this trial could contribute to the development of a new standard of care for Novacov-24 infection.</p>\n<p>\n <em>Conclusion:</em> By assessing both the effectiveness and safety of <em>Virunex-3</em>, this trial will provide valuable insights into managing Novacov-24 and preventing severe health outcomes.</p>\n
      • study_title<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • laymans_summary<p>\n This study is designed to test a new antiviral medication called <em>Virunex-3</em> to see if it can help people recover faster from an illness caused by a newly identified virus called <em>Novacov-24</em>. Participants in the study will either receive <em>Virunex-3</em> or a placebo (a pill with no active ingredients) without knowing which one they are getting. The goal is to find out if <em>Virunex-3</em> can reduce symptoms more quickly, lower the need for hospital care, and prevent serious complications. The results will help doctors understand if this new treatment is safe and effective for fighting the virus.</p>\n
      • short_titleVirunex-3 Trial for Novacov-24
      • protocol_noECCT/25/01/09 - B
      • reference_no1234redwsqa
      • version_nov1
      • date_of_protocol01-01-2025
      • study_drugVirunex-3
      • disease_conditionNovacov-24 Virus Infection
      • product_type_biologicals1
      • product_type_proteins0
      • product_type_immunologicals1
      • product_type_vaccines0
      • product_type_hormones0
      • product_type_toxoid0
      • product_type_chemical0
      • product_type_medical_device0
      • product_type_chemical_name
      • product_type_medical_device_name
      • comparatorNo
      • comparator_name
      • comparator_registered
      • comparator_countries
      • ecct_not_applicable0
      • ecct_ref_number
      • email_addressjkiprotich@intellisoftkenya.com
      • applicant_covering_letter1
      • applicant_protocol1
      • applicant_patient_information1
      • applicant_investigators_brochure1
      • applicant_investigators_cv1
      • applicant_signed_declaration1
      • applicant_financial_declaration1
      • applicant_gmp_certificate1
      • applicant_indemnity_cover1
      • applicant_opinion_letter1
      • applicant_approval_letter1
      • applicant_statement1
      • applicant_participating_countries(null)
      • applicant_addendum1
      • applicant_fees1
      • applicant_complete_form(null)
      • applicant_impd1
      • applicant_prev_data1
      • applicant_stability_data1
      • applicant_analysis_cert1
      • applicant_pictorial_sample1
      • applicant_gcp_training1
      • applicant_dsmb_charter1
      • applicant_detailed_budget1
      • applicant_indemnity_pi1
      • applicant_practice_license1
      • applicant_registration_ctr(null)
      • applicant_pan_african1
      • applicant_hard_copies(null)
      • applicant_signed_checklist1
      • statistical_analysis_plan1
      • applicant_contractual_agreement1
      • declaration_applicantOfficia quasi sunt ab ducimus eaque consectetur aut hic modi omnis
      • declaration_date110-01-2025
      • declaration_principal_investigatorCupidatat consectetur consequuntur fugiat labore necessitatibus dolore est saepe dolorem cumque aliquid aliqua In id quibusdam accusamus
      • declaration_date209-01-2025
      • protocol_not_ai_generated0
      • placebo_presentYes
      • study_objectives<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • principal_inclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • principal_exclusion_criteria<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • primary_end_points<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • scope_diagnosis1
      • scope_prophylaxis0
      • scope_therapy0
      • scope_safety0
      • scope_efficacy0
      • scope_pharmacokinetic0
      • scope_pharmacodynamic1
      • scope_bioequivalence0
      • scope_dose_response1
      • scope_pharmacogenetic0
      • scope_pharmacogenomic0
      • scope_pharmacoecomomic1
      • scope_others1
      • scope_others_specifyIn odit voluptate fu
      • trial_human_pharmacology0
      • trial_administration_humans1
      • trial_bioequivalence_study0
      • trial_other1
      • trial_other_specifyVoluptas veniam ut
      • trial_therapeutic_exploratory0
      • trial_therapeutic_confirmatory1
      • trial_therapeutic_use1
      • design_controlledYes
      • site_capacity(null)
      • staff_numbers<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_explanation<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_notapproved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_approved<p>\n A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Virunex-3 in the Treatment of Patients Infected with the Novacov-24 Virus</p>\n
      • other_details_regulatory_rejected
      • other_details_regulatory_halted
      • estimated_durationTempore id architecto quaerat ad vel
      • design_controlled_randomisedNo
      • design_controlled_openYes
      • design_controlled_single_blindNo
      • design_controlled_double_blindYes
      • design_controlled_parallel_groupNo
      • design_controlled_cross_overYes
      • design_controlled_otherYes
      • design_controlled_specifyQuo magna rerum dolor et atque adipisci esse nostrum
      • design_controlled_comparatorAut qui perspiciatis rei
      • design_controlled_other_medicinalNo
      • design_controlled_placeboNo
      • design_controlled_medicinal_otherYes
      • design_controlled_medicinal_specifySed iste tempore quia tempore tempor repudiandae molestias explicabo Omnis cum et asperiores vel est
      • single_site_member_stateNo
      • location_of_area
      • single_site_physical_address
      • single_site_contact_person
      • single_site_telephone
      • multiple_sites_member_stateYes
      • multiple_countriesYes
      • multiple_member_states668
      • number_of_sites9
      • multi_country_listAdipisicing et numqu
      • data_monitoring_committeeYes
      • total_enrolment_per_siteVitae voluptatem se
      • total_participants_worldwideAutem ut aut commodo quas eaque velit dolore proident adipisicing eaque lorem sunt doloribus dolor quo pariatur
      • population_less_than_18_yearsYes
      • population_uteroYes
      • population_preterm_newbornYes
      • population_newbornYes
      • population_infant_and_toddlerNo
      • population_childrenYes
      • population_adolescentNo
      • population_above_18Yes
      • population_adultNo
      • population_elderlyNo
      • gender_female1
      • gender_male0
      • subjects_healthyNo
      • subjects_patientsYes
      • subjects_vulnerable_populationsYes
      • subjects_women_child_bearingNo
      • subjects_women_using_contraceptionYes
      • subjects_pregnant_womenNo
      • subjects_nursing_womenYes
      • subjects_emergency_situationNo
      • subjects_incapable_consentYes
      • subjects_specifyId tempora omnis vol
      • subjects_othersYes
      • subjects_others_specifyUllam laborum Eos
      • investigator1_given_nameIlliana Ferguson
      • investigator1_middle_nameAllen Fox
      • investigator1_family_nameYolanda Rivera
      • investigator1_qualificationAut labore non sed sed aut iusto et asperiores eu ut ut do qui ullam aut obcaecati earum modi in
      • investigator1_professional_addressEst doloremque dolores adipisicing quidem laboris voluptates vitae ex
      • investigator1_telephone+1 (621) 831-1153
      • investigator1_emailqeryrilu@mailinator.com
      • organisations_transferred_Yes
      • number_participantsMinim dolor commodo
      • notification
      • approval_date13-01-2025
      • submitted1
      • deleted0
      • deleted_date(null)
      • deactivated0
      • date_submitted22-01-2025
      • unsubmitted1
      • initial_date_submitted22-01-2025
      • admin_stopped0
      • admin_stopped_reason(null)
      • approved2
      • approved_reasonThis is approved
      • approved_date(null)
      • final_report(null)
      • implication_results(null)
      • quantity_imported(null)
      • quantity_dispensed(null)
      • quantity_destroyed(null)
      • quantity_exported(null)
      • balance_site(null)
      • final_date(null)
      • ecitizen_invoice324073
      • modified2025-02-13 08:07:46
      • created2025-01-22 11:13:13
      • ai_content(null)
    • InvestigatorContact(array)
      • 0(array)
        • id92
        • application_id159
        • given_nameHiroko Lewis
        • middle_nameTatyana Medina
        • family_nameCastor Gallagher
        • qualificationQuis molestiae voluptate aut aliquam velit est consequat Asperiores possimus et neque molestias aliqua Omnis voluptas non dolor nulla laudantium
        • professional_addressNisi qui dolor optio tempore quisquam laborum Suscipit
        • telephone+1 (322) 766-3057
        • emailtipyhuqo@mailinator.com
        • investigator_roleprincipal
        • created2025-01-13 12:13:08
        • modified2025-02-13 08:07:46
    • SiteDetail(array)
      • 0(array)
        • id1710
        • application_id159
        • county_id38
        • site_nameAhmed Trujillo
        • physical_addressDolorum dolores necessitatibus minus magna quo velit eveniet temporibus accusantium eveniet maxime reprehenderit consectetur ipsum ea aut
        • contact_detailsP.O. Box 10
        • contact_personExcepturi culpa dolore vero ut blanditiis aliquam error exercitation dolore reiciendis harum molestiae molestiae magnam fugit
        • site_capacity(null)
        • misc(null)
        • created2025-01-13 12:13:08
        • modified2025-02-13 08:07:46
        • County(array)
          • id38
          • county_nameVihiga
          • created2012-06-15 10:26:37
          • modified2012-06-15 10:26:37
    • Sponsor(array)
      • 0(array)
        • id40
        • application_id159
        • sponsorEnim sint voluptatem eos nobis reiciendis dolore et qui corrupti quod minim pariatur Possimus
        • sponsor_typeLocal Kenyan Investigator
        • contact_personDolorem mollitia id quis provident error voluptatem voluptate
        • addressDolore laborum delectus dolor corrupti rerum aut magnam impedit quia cillum et cupiditate aliquid sapiente
        • telephone_number+1 (666) 325-1183
        • fax_number+1 (314) 248-5575
        • cell_number+1 (134) 102-6236
        • email_addresstuhokelyh@mailinator.com
        • created2025-01-13 12:13:08
        • modified2025-02-13 08:07:46
    • PublicAction(array)
      • labelApproved
      • date13-01-2025
• page_options(array)
  • 1010
  • 5050
  • 100100
• redir
• $request->data(array)
  • Application(array)
    • statusapproved
• $this->validationErrors(array)
  • Permission(empty)
  • Aro(empty)
  • Aco(empty)
  • Application(empty)
  • User(empty)
  • TrialStatus(empty)
  • InvestigatorContact(empty)
  • Sponsor(empty)
  • SiteDetail(empty)
  • County(empty)
• Loaded Helpers(array)
  • 0Html
  • 1Form
  • 2Session
  • 3Text
  • 4Number
  • 5SimpleGraph
  • 6Paginator
  • 7DebugTimer
  • 8Toolbar
  • 9HtmlToolbar

App Constants

CakePHP Constants

PHP Environment

Included Files

Include Paths

• 0/var/www/ctr/app/Plugin/Media/Lib/mm/src
• 1/var/www/ctr/lib
• 3/usr/share/php
• 4-> /var/www/ctr/lib/Cake/

Included Files

• core(array)
  • Behavior(array)
    • 0CORE/Model/Behavior/TreeBehavior.php
    • 1CORE/Model/Behavior/ContainableBehavior.php
    • 2CORE/Model/Behavior/AclBehavior.php
  • Cache(array)
    • 0CORE/Cache/Cache.php
    • 1CORE/Cache/Engine/FileEngine.php
    • 2CORE/Cache/CacheEngine.php
  • Component(array)
    • 0CORE/Controller/Component/AclComponent.php
    • 1CORE/Controller/Component/Acl/DbAcl.php
    • 2CORE/Controller/Component/Acl/AclInterface.php
    • 3CORE/Controller/Component/AuthComponent.php
    • 4CORE/Controller/Component/RequestHandlerComponent.php
    • 5CORE/Controller/Component/SessionComponent.php
    • 6CORE/Controller/Component/PaginatorComponent.php
  • Config(array)
    • 0CORE/Config/routes.php
    • 1CORE/Config/config.php
  • Controller(array)
    • 0CORE/Controller/Controller.php
    • 1CORE/Controller/ComponentCollection.php
    • 2CORE/Controller/Component.php
  • Datasource(array)
    • 0CORE/Model/Datasource/CakeSession.php
    • 1CORE/Model/Datasource/Database/Mysql.php
    • 2CORE/Model/Datasource/DboSource.php
    • 3CORE/Model/Datasource/DataSource.php
  • Error(array)
    • 0CORE/Error/exceptions.php
    • 1CORE/Error/ErrorHandler.php
  • I18n(array)
    • 0CORE/I18n/I18n.php
    • 1CORE/I18n/L10n.php
  • Log(array)
    • 0CORE/Log/CakeLog.php
    • 1CORE/Log/LogEngineCollection.php
    • 2CORE/Log/Engine/FileLog.php
    • 3CORE/Log/Engine/BaseLog.php
    • 4CORE/Log/CakeLogInterface.php
  • Model(array)
    • 0CORE/Model/ConnectionManager.php
    • 1CORE/Model/Permission.php
    • 2CORE/Model/Model.php
    • 3CORE/Model/BehaviorCollection.php
    • 4CORE/Model/Aro.php
    • 5CORE/Model/AclNode.php
    • 6CORE/Model/Aco.php
    • 7CORE/Model/ModelBehavior.php
  • Network(array)
    • 0CORE/Network/CakeRequest.php
    • 1CORE/Network/CakeResponse.php
  • Other(array)
    • 0CORE/bootstrap.php
    • 1CORE/basics.php
    • 2CORE/Core/App.php
    • 3CORE/Core/Configure.php
    • 4CORE/Core/CakePlugin.php
    • 5CORE/Event/CakeEventListener.php
    • 6CORE/Event/CakeEvent.php
    • 7CORE/Event/CakeEventManager.php
    • 8CORE/Core/Object.php
  • Routing(array)
    • 0CORE/Routing/Dispatcher.php
    • 1CORE/Routing/Filter/AssetDispatcher.php
    • 2CORE/Routing/DispatcherFilter.php
    • 3CORE/Routing/Filter/CacheDispatcher.php
    • 4CORE/Routing/Router.php
    • 5CORE/Routing/Route/CakeRoute.php
    • 6CORE/Routing/Route/PluginShortRoute.php
  • Utility(array)
    • 0CORE/Utility/Hash.php
    • 1CORE/Utility/Inflector.php
    • 2CORE/Utility/ObjectCollection.php
    • 3CORE/Utility/Debugger.php
    • 4CORE/Utility/String.php
    • 5CORE/Utility/ClassRegistry.php
    • 6CORE/Utility/Set.php
    • 7CORE/Utility/Sanitize.php
  • View(array)
    • 0CORE/View/HelperCollection.php
• app(array)
  • Behavior(array)
    • 0APP/Model/Behavior/SoftDeleteBehavior.php
  • Config(array)
    • 0APP/Config/core.php
    • 1APP/Config/bootstrap.php
    • 2APP/Config/routes.php
    • 3APP/Config/database.php
  • Controller(array)
    • 0APP/Controller/ApplicationsController.php
    • 1APP/Controller/AppController.php
  • Model(array)
    • 0APP/Model/AppModel.php
    • 1APP/Model/Application.php
    • 2APP/Model/User.php
    • 3APP/Model/TrialStatus.php
    • 4APP/Model/InvestigatorContact.php
    • 5APP/Model/Sponsor.php
    • 6APP/Model/SiteDetail.php
    • 7APP/Model/County.php
  • Other(array)
    • 0APP/webroot/index.php
• plugins(array)
  • CakePdf(array)
    • Config(array)
      • 0CakePdf/Config/bootstrap.php
      • 1CakePdf/Config/routes.php
  • CakeResque(array)
    • Config(array)
      • 0CakeResque/Config/bootstrap.php
    • Plugin(array)
      • 0CakeResque/Lib/CakeResque.php
      • 1CakeResque/vendor/kamisama/php-resque-ex/lib/Resque.php
      • 2CakeResque/vendor/kamisama/php-resque-ex/lib/Resque/Event.php
      • 3CakeResque/vendor/kamisama/php-resque-ex/lib/Resque/Exception.php
  • DebugKit(array)
    • Component(array)
      • 0DebugKit/Controller/Component/ToolbarComponent.php
    • Plugin(array)
      • 0DebugKit/Lib/DebugMemory.php
      • 1DebugKit/Lib/Panel/HistoryPanel.php
      • 2DebugKit/Lib/DebugPanel.php
      • 3DebugKit/Lib/Panel/SessionPanel.php
      • 4DebugKit/Lib/Panel/RequestPanel.php
      • 5DebugKit/Lib/Panel/SqlLogPanel.php
      • 6DebugKit/Lib/Panel/TimerPanel.php
      • 7DebugKit/Lib/Panel/LogPanel.php
      • 8DebugKit/Lib/Log/Engine/DebugKitLog.php
      • 9DebugKit/Lib/Panel/VariablesPanel.php
      • 10DebugKit/Lib/Panel/EnvironmentPanel.php
      • 11DebugKit/Lib/Panel/IncludePanel.php
      • 12DebugKit/Lib/DebugTimer.php
  • Media(array)
    • Config(array)
      • 0Media/Config/bootstrap.php
    • Plugin(array)
      • 0Media/Lib/mm/src/Mime/Type.php
      • 1Media/Lib/mm/src/Mime/Type/Magic/Adapter/Fileinfo.php
      • 2Media/Lib/mm/src/Mime/Type/Magic/Adapter.php
      • 3Media/Lib/mm/src/Mime/Type/Glob/Adapter/Memory.php
      • 4Media/Lib/mm/src/Mime/Type/Glob/Adapter.php
      • 5Media/Lib/mm/src/Media/Process.php
      • 6Media/Lib/mm/src/Media/Info.php
  • Search(array)
    • Component(array)
      • 0Search/Controller/Component/PrgComponent.php
    • Behavior(array)
      • 0Search/Model/Behavior/SearchableBehavior.php
  • Shim(array)
    • Config(array)
      • 0Shim/Config/bootstrap.php
  • Tools(array)
    • Config(array)
      • 0Tools/Config/bootstrap.php